Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* In good general health~* Have 5 to 20 AKs on the face or balding scalp~* Negative urine pregnancy test (for women who are able to become pregnant)~* Willing to make frequent visits to the study center during treatment and follow-up periods.~Exclusion Criteria:~* Women who are pregnant, lactating or planning to become pregnant during the study.~* Have had a medical event within 90 days of the first visit (such as; stroke, heart attack).~* Have any skin condition in the treatment area that may be made worse by treatment with imiquimod (e.g., rosacea, psoriasis, atopic dermatitis, eczema).~* Have received specific treatments/medications in the treatment area(s) within the designated time period prior to study treatment initiation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3.75% imiquimod cream (Type: ACTIVE_COMPARATOR): None
- 2.5% imiquimod cream (Type: ACTIVE_COMPARATOR): None
- Placebo cream (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).